Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has been given an average recommendation of “Buy” by the seven analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $43.40.
DCPH has been the topic of a number of research analyst reports. JPMorgan Chase & Co. initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set an “overweight” rating and a $30.00 target price on the stock. Instinet initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set a “buy” rating and a $57.00 target price on the stock. JMP Securities initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set an “outperform” rating and a $38.00 target price on the stock. Zacks Investment Research lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 15th. Finally, BidaskClub raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd.
Deciphera Pharmaceuticals (NASDAQ:DCPH) traded up $0.98 during trading hours on Tuesday, reaching $28.92. The company had a trading volume of 115,549 shares, compared to its average volume of 195,728. Deciphera Pharmaceuticals has a 1 year low of $15.15 and a 1 year high of $29.48.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Emerald Advisers Inc. PA increased its stake in Deciphera Pharmaceuticals by 37.6% in the 4th quarter. Emerald Advisers Inc. PA now owns 482,626 shares of the company’s stock worth $10,941,000 after purchasing an additional 131,886 shares in the last quarter. Orbimed Advisors LLC purchased a new position in Deciphera Pharmaceuticals in the 3rd quarter worth about $7,487,000. BlackRock Inc. increased its stake in Deciphera Pharmaceuticals by 3,989.6% in the 4th quarter. BlackRock Inc. now owns 363,483 shares of the company’s stock worth $8,241,000 after purchasing an additional 354,595 shares in the last quarter. Emerald Mutual Fund Advisers Trust purchased a new position in Deciphera Pharmaceuticals in the 3rd quarter worth about $5,548,000. Finally, Citadel Advisors LLC purchased a new position in Deciphera Pharmaceuticals in the 3rd quarter worth about $4,965,000. 44.93% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/deciphera-pharmaceuticals-inc-dcph-receives-consensus-rating-of-buy-from-brokerages-2.html.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.